alexa PANDEMIC INFLUENZA A(H1N1)V VIRUSES CURRENTLY CIRCULATING IN NEW ZEALAND ARE SENSITIVE TO OSELTAMIVIR
Immunology

Immunology

Journal of Vaccines & Vaccination

Author(s): R J Hall, M P Peacey, J C Ralston, J Bocacao, M Ziki

Abstract Share this page

Since the declaration of a pandemic by the World Health Organisation on 12 June 2009, New Zealand has seen a surge in the number of cases of pandemic influenza A(H1N1)v. As of 16 July 2009, there have been 2,107 laboratory-confirmed cases in New Zealand and 10 deaths; the actual number of infections is certainly much higher. Like other southern hemisphere countries with a temperate climate, New Zealand entered the winter period with seasonal influenza activity. The national influenza surveillance system detected co-circulation of pandemic A(H1N1)v virus and seasonal influenza strains. Infection with pandemic A(H1N1)v has rapidly outnumbered seasonal influenza viruses within just a month [1]. The current recommended antiviral drug for treatment of pandemic A(H1N1)v is the neuraminidase inhibitor oseltamivir (Tamiflu®). Oseltamivir has been used in New Zealand to limit entry and spread of the virus since an initial incursion on 26 April 2009, for the treatment of quarantined cases and as prophylaxis for close contacts during the containment phase, and now mainly for the treatment of cases during the management phase.

  • To read the full article Visit
  • Open Access
This article was published in Eurosurveillance and referenced in Journal of Vaccines & Vaccination

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords